Anti-RSPO3 Antibody, Non-Fucosylated (BioBet-1578ZP) (CAT#: BioBet-1578ZP) Datasheet

RSPO3

R-spondin 3

This gene belongs to the R-spondin family. The encoded protein plays a role in the regulation of Wnt (wingless-type MMTV integration site family)/beta-catenin and Wnt/planar cell polarity (PCP) signaling pathways, which are involved in development, cell growth and disease pathogenesis. Genome-wide association studies suggest a correlation of this gene with bone mineral density and risk of fracture. This gene may be involved in tumor development. [provided by RefSeq, Jul 2013]

RSPO3; R-spondin 3; PWTSR; THSD2; CRISTIN1; R-spondin-3; R-spondin 3 homolog; roof plate-specific spondin-3; protein with TSP type-1 repeat; thrombospondin, type I, domain containing 2; thrombospondin type-1 domain-containing protein 2;

Extracellular region or secreted

Diseases associated with RSPO3 include Nail Disorder, Nonsyndromic Congenital, 4.

Its related pathways are Signaling by GPCR and Signaling by Wnt.

As the ligand of LGR4-6 receptor, it is the activator of typical Wnt signaling pathway, and LGR4-6 receptor is a key regulator of angiogenesis. After binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 binds to phosphorylated LRP6 and frizzled receptors activated by extracellular Wnt receptors, triggering a typical Wnt signaling pathway to increase the expression of target genes. It also regulates the canonical Wnt/ -catenin-dependent pathway and the non-canonical Wnt signal pathway by being an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. As a ligand for curled FZD8 and LRP6. It may negatively regulate the tgf-pathway. By controlling blood vessel stability and pruning, it is a key regulator of angiogenesis: by activating atypical Wnt signaling pathways in endothelial cells (similarity). It can also amplify the Wnt signaling pathway independently of LGR4-6 receptor, possibly as a direct antagonist of RNF43 and ZNRF3.

1.Glycosylation at Asn36 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

OMP-131R10

Human

Human

Anti-RSPO3 is the first drug in its class to target the R-spondin-LGR pathway, and has shown robust preclinical activity against a number of solid tumor types.

Cancer

Cancer